Early Blood Pressure Reduction by Intravenous Vasodilators Is Associated With Acute Kidney Injury in Patients With Hypertensive Acute Decompensated Heart.


Journal

Circulation journal : official journal of the Japanese Circulation Society
ISSN: 1347-4820
Titre abrégé: Circ J
Pays: Japan
ID NLM: 101137683

Informations de publication

Date de publication:
23 08 2019
Historique:
pubmed: 19 7 2019
medline: 29 7 2020
entrez: 19 7 2019
Statut: ppublish

Résumé

Intravenous vasodilators are commonly used in patients with hypertensive acute decompensated heart failure (ADHF), but little is known about their optimal use in blood pressure (BP) management to avoid acute kidney injury (AKI). The purpose of this study was to investigate the association between systolic BP (SBP) changes and the incidence of AKI in patients with hypertensive ADHF.Methods and Results:Post-hoc analysis was performed on a prospectively enrolled cohort. We investigated 245 patients with ADHF and SBP >140 mmHg on arrival (mean age, 76 years; 40% female). We defined "SBP-fall" as the maximum percent reduction in SBP 6 h after intravenous treatment. AKI was defined as serum creatinine (SCr) ≥0.3 mg/dL, or urine output <0.5 mL/kg/h (n=66) at 48 h. Mean SBP and SCr levels on arrival were 180 mmHg and 1.21 mg/dL, respectively. Patients with AKI had significantly larger SBP-fall than the others (36.7±15.3% vs. 27.2±15.3%, P<0.0001). Logistic regression analysis showed an odds ratio per 10% SBP-fall for AKI of 1.49 (95% confidence interval 1.29-1.90, P=0.001). SBP-fall was significantly associated with the number of concomitant used intravenous vasodilators (P=0.001). The administration of carperitide was also independently associated with increased incidence of AKI. Larger SBP-fall from excessive vasodilator use is associated with increased incidence of AKI in patients with hypertensive ADHF.

Sections du résumé

BACKGROUND
Intravenous vasodilators are commonly used in patients with hypertensive acute decompensated heart failure (ADHF), but little is known about their optimal use in blood pressure (BP) management to avoid acute kidney injury (AKI). The purpose of this study was to investigate the association between systolic BP (SBP) changes and the incidence of AKI in patients with hypertensive ADHF.Methods and Results:Post-hoc analysis was performed on a prospectively enrolled cohort. We investigated 245 patients with ADHF and SBP >140 mmHg on arrival (mean age, 76 years; 40% female). We defined "SBP-fall" as the maximum percent reduction in SBP 6 h after intravenous treatment. AKI was defined as serum creatinine (SCr) ≥0.3 mg/dL, or urine output <0.5 mL/kg/h (n=66) at 48 h. Mean SBP and SCr levels on arrival were 180 mmHg and 1.21 mg/dL, respectively. Patients with AKI had significantly larger SBP-fall than the others (36.7±15.3% vs. 27.2±15.3%, P<0.0001). Logistic regression analysis showed an odds ratio per 10% SBP-fall for AKI of 1.49 (95% confidence interval 1.29-1.90, P=0.001). SBP-fall was significantly associated with the number of concomitant used intravenous vasodilators (P=0.001). The administration of carperitide was also independently associated with increased incidence of AKI.
CONCLUSIONS
Larger SBP-fall from excessive vasodilator use is associated with increased incidence of AKI in patients with hypertensive ADHF.

Identifiants

pubmed: 31316033
doi: 10.1253/circj.CJ-19-0333
doi:

Substances chimiques

Antihypertensive Agents 0
Vasodilator Agents 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1883-1890

Auteurs

Yoshihito Arao (Y)

Department of Cardiology, Nagoya University Graduate School of Medicine.

Akinori Sawamura (A)

Department of Cardiology, Nagoya University Graduate School of Medicine.
Department of Cardiology, Ichinomiya Municipal Hospital.

Masahiro Nakatochi (M)

Data Science Division, Data Coordinating Center, Department of Advanced Medicine, Nagoya University Hospital.

Takahiro Okumura (T)

Department of Cardiology, Nagoya University Graduate School of Medicine.

Hiroo Kato (H)

Department of Cardiology, Nagoya University Graduate School of Medicine.

Hideo Oishi (H)

Department of Cardiology, Nagoya University Graduate School of Medicine.

Shogo Yamaguchi (S)

Department of Cardiology, Nagoya University Graduate School of Medicine.

Tomoaki Haga (T)

Department of Cardiology, Nagoya University Graduate School of Medicine.

Tasuku Kuwayama (T)

Department of Cardiology, Nagoya University Graduate School of Medicine.

Tsuyoshi Yokoi (T)

Department of Cardiology, Nagoya University Graduate School of Medicine.

Hiroaki Hiraiwa (H)

Department of Cardiology, Nagoya University Graduate School of Medicine.

Toru Kondo (T)

Department of Cardiology, Nagoya University Graduate School of Medicine.

Ryota Morimoto (R)

Department of Cardiology, Nagoya University Graduate School of Medicine.

Toyoaki Murohara (T)

Department of Cardiology, Nagoya University Graduate School of Medicine.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH